BioSpace News Archive

Learn some effective exit strategy to leave you cu

When Quitting is Your Best Option: How to Create Your Exit Strategy

Do you think it’s time to quit your job? If you are certain that you want to quit, do you have an exit strategy? If not then reading this article is a must for you.

May 22, 2018

·

3 min read

·

Porschia Parker

Drug Development

uniQure, Bioverativ Unveil Positive Data for Hemophilia B and Hemophilia A Patients

Hemophilia B patients have some good news to cheer. Data suggests that uniQure’s AAV5 gene therapy may be viable treatments for 97 percent of patients. However, uniQure wasn’t the only company touting positive news in the treatment of hemophilia.

May 22, 2018

·

3 min read

·

Alex Keown

Red trend as symbol of business recession and financial crisis. Large resolution

Drug Development

Sesen Bio Shares Plunge Despite Reporting Positive Interim Phase III Results

Shares of newly dubbed Sesen Bio (formerly Eleven Biotherapeutics) have plunged 23 percent after the company released positive, three-month data from its ongoing Phase III high-grade non-muscle invasive bladder cancer (NMIBC) trial.

May 22, 2018

·

2 min read

·

Alex Keown

Lonza Further Strengthens Hepatocytes Portfolio with Addition of Hepatic Non-Parenchymal Cells

Lonza announced the addition of hepatic stellate cells, Kupffer cells and liver-derived endothelial cells to its extensive hepatocytes portfolio.

May 22, 2018

·

4 min read

Hand showing money in network. The concept of electronic money.

Biotech Bay

GRAIL Grabs $300 Million Ahead of Possible IPO on Hong Kong Exchange

With a new chief executive officer on board, GRAIL, Inc. has secured a whopping $300 million in an oversubscribed Series C financing round led by multiple Chinese investment groups.

May 22, 2018

·

3 min read

·

Alex Keown

Deals

Ahead of the Takeda-Shire Takeover, Takeda Selling Chinese Joint Venture

With the acquisition of Dublin-based Shire by Japan-based Takeda Pharmaceutical pretty much a done-deal, Takeda appears to be getting its financial house in order before it closes.

May 22, 2018

·

2 min read

·

Mark Terry

3 More Moderna R&D Execs Quietly Step Down

Business

Significant Bloc of AstraZeneca Shareholders Reject Executive Remuneration Plan

AstraZeneca has a problem. Not with its pipeline, but with the way a significant chunk of shareholders views its executive pay program.

May 22, 2018

·

2 min read

·

Alex Keown

$710M Gamble Fails as Celgene Terminates Two Phase

Business

Celgene’s Deal Boss Golumbeski Made a Quiet Exit in April

Celgne’s head of business development, George Golumbeski, has also left the company.

May 22, 2018

·

3 min read

·

Mark Terry

Deals

Who are the Top 3 Biotech Takeover Targets?

Most investors thought 2018 would be a big year for mergers and acquisitions in the biopharma industry because of changes to the tax law, and so far they’ve been right.

May 22, 2018

·

3 min read

·

Mark Terry

Drug Development

Approved! FDA gives Dova Pharma’s Doptelet a Thumbs Up

Dova Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) approved its Doptelet (avatrombopag) to treat thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure.

May 22, 2018

·

2 min read

·

Mark Terry